Drug Profile
Research programme: TNF pathway modulators - Rigel
Alternative Names: TNF pathway modulators research programme - RigelLatest Information Update: 11 Nov 2005
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Class
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 10 Nov 2005 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 10 Apr 2000 New profile
- 10 Apr 2000 Preclinical development for Inflammation in USA (Unknown route)